Research published in the International Journal of Data Science has used machine learning to predict the lifecycle of ...

The situation boils down to an unauthorized generic of Vertex’s top-selling CF med Trikafta marketed in Russia. Since January, the Russian Ministry of Health has been switching children who take ...

Trikafta, made by Vertex Pharmaceuticals, is, as its name suggests, a combination of three drugs. It works for 90 percent of patients with cystic fibrosis, and will be priced at $311,000 per year.

The company’s total revenues of $2.77 billion rose 3% year over year, driven by higher sales of its triple combination cystic fibrosis (CF) therapy Trikafta/Kaftrio and an early contribution ...